Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net concizumab‑mtci (Alhemo) Coverage Updat…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CP.PHAR.625

    Concizumab-mtci (Alhemo) prophylaxis for hemophilia A and B

    Customize your policy alerts

    Sign up for Health Net Policy CP.PHAR.625 alerts

    Get alerted when Policy CP.PHAR.625 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for Alhemo (concizumab-mtci) when used for routine prophylaxis to prevent or reduce bleeding in patients ≥12 years with hemophilia A or B, with or without inhibitors. Applies to Health Net lines of business listed in the policy.

    Policy Summary
    PayerHealth Net
    PolicyConcizumab-mtci (Alhemo) prophylaxis for hemophilia A and B
    Policy CodePolicy CP.PHAR.625
    Change TypeMaterial coverage and operational updates (codes, indications, approval durations, exclusions)
    Effective DateDec 20, 2024
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation demonstrating diagnosis, prescriber specialty, weight, prior therapy failures or contraindications, dosing, and relevant plasma concentration data.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS code J7173 (Injection, concizumab-mtci, 0.5 mg) was added to the policy.

    Requirements for documentation and provider attestations of Concizumab ELISA were removed.

    Initial and continued approval durations were modified for Medicaid/HIM and Commercial lines of business.

    New indication added for hemophilia A and B without inhibitors.

    Provider confirmation of discontinuation of prophylactic hemophilia agents changed to an exclusion for concurrent use, with examples for on-demand use.

    ≥12minimum covered patient age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J7173HCPCS code added
    0.25 mg/kg/daymax maintenance dose
    12 moapproval duration (Medicaid/HIM)
    6 moapproval duration (Commercial)

    Coverage Criteria for Concizumab-mtci (Alhemo)

    Initial Therapy - Without Inhibitors

    Covered when ALL of the following are met for congenital hemophilia A or B without inhibitors (initial therapy):

    Diagnosis: Prescribed for routine prophylaxis of bleeding episodes in members with congenital hemophilia A (FVIII deficiency) without inhibitors OR congenital hemophilia B (FIX deficiency) without inhibitors.
    Prescriber: Prescribed by or in consultation with a hematologist.
    Age ≥ 12 years.
    Severity or bleed history for those new to prophylaxis: For members new to Alhemo therapy and not previously using FVIII or FIX products for routine prophylaxis: member meets one of the following: (a) severe hemophilia A defined as FVIII < 1%; (b) moderately severe to severe hemophilia B defined as FIX ≤ 2%; or (c) experienced at least one serious spontaneous bleed (see Appendix D).

    See Appendix D for definitions of serious bleed and spontaneous bleed.

    Prior therapy requirements (hemophilia A): For hemophilia A: failure of a FVIII product used for routine prophylaxis AND failure of Hemlibra, as assessed and documented by prescriber, unless contraindicated or clinically significant adverse effects are experienced.

    Prior authorization may be required for comparator products.

    Prior therapy requirements (hemophilia B): For hemophilia B: failure of a FIX product used for routine prophylaxis as assessed and documented by prescriber, unless contraindicated or clinically significant adverse effects are experienced.

    Prior authorization may be required for comparator products.

    Concurrent therapy: Alhemo is not prescribed concurrently with another hemophilia prophylaxis agent (e.g., prophylactic FVIII/FIX products, Qfitlia, Hympavzi, Hemlibra). On-demand usage of FVIII or FIX may be continued.
    Weight: Documentation of current body weight (kg).
    Dosing limits: Dose does not exceed both of the following: one loading dose of 1 mg/kg and maintenance dose of 0.25 mg/kg per day.

    Initial Therapy - With Inhibitors

    Covered when ALL of the following are met for congenital hemophilia A or B with inhibitors (initial therapy):

    Diagnosis: Prescribed for routine prophylaxis of bleeding episodes in members with congenital hemophilia A or B with inhibitors.
    Prescriber: Prescribed by or in consultation with a hematologist.
    Age ≥ 12 years.
    Prior therapy (hemophilia A with inhibitors): For hemophilia A with inhibitors: failure of Hemlibra as assessed and documented by prescriber, unless contraindicated or clinically significant adverse effects are experienced.

    Prior authorization may be required for Hemlibra.

    Concurrent therapy:

    Continued Therapy

    Covered when ALL of the following are met for continued therapy (with or without inhibitors):

    Eligibility for continuation: Member is currently receiving medication via Centene benefit or previously met initial approval criteria OR member is currently receiving medication and is enrolled in a state/product with continuity of care regulations.

    Refer to state-specific addendums.

    Clinical response: Member is responding positively to therapy (e.g., reduction in number of all bleeds, joint bleeds, and/or target joint bleeds over time).
    Concurrent therapy: Alhemo is not prescribed concurrently with another hemophilia prophylaxis agent (e.g., bypassing agents, prophylactic FVIII/FIX products, Qfitlia, Hympavzi, Hemlibra); on-demand use may continue.
    Weight: Documentation of current body weight (kg).

    Initial and ongoing coverage criteria

    Covered when ALL of the following are met

    Routine prophylaxis dosing and indication: Member has hemophilia A or B for routine prophylaxis of bleeding episodes (with or without inhibitors).

    Policy added indication for hemophilia without inhibitors.

    Dosing regimen: Initial loading dose 1 mg/kg SC once, followed by maintenance 0.2 mg/kg SC once daily starting 4 weeks after initiation; maintenance dose may be individualized up to 0.25 mg/kg SC once daily if Alhemo plasma concentration ≤ 200 ng/mL per Appendix D.

    Plasma concentration thresholds detailed in Appendix D; ELISA monitoring documentation requirements were removed in 2Q2026.

    Concurrent prophylaxis exclusion: Concurrent prophylactic use of Hemlibra, bypassing agents, FVIII, or FIX products is excluded and will preclude coverage; on-demand use of such agents is allowable as described in policy.

    Provider confirmation of discontinuation of prophylactic agents was revised to be an exclusion for concurrent use.

    Non‑FDA approved (off‑label) indications that are not specifically addressed in this policy are not authorized unless the prescriber provides sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace/ICHRA, or CP.PMN.53 for Medicaid.

    Concurrent prophylactic use of other hemophilia prophylaxis agents while a member is receiving Alhemo is expressly excluded and will preclude coverage; the policy clarifies that on‑demand use of factor or bypassing agents is allowable as described elsewhere in the policy.

    The policy does not allow concurrent use of Alhemo with other prophylactic hemophilia agents (for example, Hemlibra, prophylactic FVIII/FIX products, or bypassing agents). Concurrent prophylactic therapy is an exclusion and may result in denial if not discontinued prior to authorization.

    Coding and Laboratory Thresholds

    Covered HCPCS CodesHCPCSCovered
    J7173Injection, concizumab-mtci, 0.5 mg
    Previously used HCPCS Codes (removed)HCPCSNot Covered
    C9399Unclassified drugs or biologicals (removed)
    J3590Unclassified biologics (removed)
    Alhemo plasma concentration — value bands used in dosing/monitoring
    Alhemo plasma concentration band≤ 200 ng/mL
    Alhemo plasma concentration band200 to 4,000 ng/mL
    Alhemo plasma concentration band> 4,000 ng/mL
    FVIII level for severe hemophilia A
    FVIII threshold (severe hemophilia A)< 1%
    ContextUsed to define severe hemophilia A for eligibility when new to prophylaxis
    Source appendix reference

    Provider Requirements, Prior Authorization, and Billing

    Prior Authorization

    Prior authorization required

    Prior authorization is required. Prescribers must document the diagnosis, prescriber specialty (hematologist or in consultation with a hematologist), member age (≥12 years), current body weight (kg), dosing (loading and maintenance) and prior therapy failures or contraindications for both initial and continued therapy per the policy.

    • Document diagnosis (hemophilia A or B, with or without inhibitors).
    • Document prescriber specialty or consultation with a hematologist.
    • Include current body weight (kg), dosing plan, and prior therapy failures or reasons alternatives are not used.
    Billing Rule

    Prior authorization and billing code

    Initial Therapy Criteria and Dosing

    Initial Therapy (drug-specific)

    Initial therapy criteria for patients with and without inhibitors:

    Prescriber: Prescribed by or in consultation with a hematologist.
    Age ≥ 12 years.
    Eligibility for new-to-therapy patients: Severe hemophilia A (FVIII < 1%) OR moderately severe to severe hemophilia B (FIX ≤ 2%) OR at least one serious spontaneous bleed.
    Prior therapy: Documented failure of FVIII/FIX products and/or Hemlibra as applicable and assessed/documented by prescriber unless contraindicated.

    Prior authorization may be required for comparator products.

    Criteria for Continued Therapy

    Continuation Therapy

    Continuation requires evidence of benefit and monitoring of plasma concentrations.

    Prior use or prior criteria met: Member is currently receiving medication via Centene benefit or previously met initial approval criteria (or continuity of care applies).
    Response: Member is responding positively to therapy (e.g., fewer bleeds).
    Plasma concentration: Member has not had 2 consecutive Alhemo plasma concentrations < 200 ng/mL.

    Dose adjustments according to plasma concentration ranges (see Appendix D).

    Continued therapy and monitoring

    Continued therapy requirements and durations as updated in 2Q2026

    Step Therapy Requirements and Exceptions

    StepRequirement (documented failure unless contraindicated)Notes / Exceptions
    1
    For hemophilia A without inhibitors: Failure of a FVIII product used for routine prophylaxis as assessed and documented by prescriber.
    Prior authorization may be required for comparator FVIII products; IL HIM step therapy requirement does not apply as of 1/1/2026 per IL HB 5395.
    Line of Business / ProgramStep Therapy Bypass RuleSupporting Reference
    Illinois HIM
    Step therapy requirements are bypassed for Illinois HIM requests effective 1/1/2026 per IL HB 5395; step therapy bypass was added to policy for IL HIM.
    IL HB 5395 operational exception; referenced in policy coding/operational notes.

    Product Strengths and Quantity Information

    Concizumab-mtci (Alhemo) — product strengths available
    Strength60 mg / 1.5 mL (40 mg/mL)
    Strength150 mg / 1.5 mL (100 mg/mL)
    Strength300 mg / 3 mL (100 mg/mL)

    Site of Care and Administration

    Note

    Product supplied as prefilled pens; no site restriction specified

    Product is supplied as single‑patient‑use prefilled pens and the policy does not specify an administration site restriction; providers may note product availability when planning treatment.

    • Available as single‑patient‑use prefilled pens in 60 mg, 150 mg, and 300 mg strengths.
    • Administration setting is not specified as a restriction in the policy.
    Note

    Prefilled pens suitable for self‑administration (home use)

    Concizumab is provided in single‑patient‑use prefilled pens suitable for self‑administration; the policy notes suitability for self‑administration and does not restrict site of care.

    • Prefilled pens intended for single‑patient use and suitable for self‑administration.
    • No site‑of‑care restriction is specified in the policy.

    Definitions and Clinical Terms

    Spontaneous bleed — definition used in criteria
    DefinitionA bleeding episode that occurs without apparent cause and is not the result of trauma.
    UsageApplied to determine eligibility for initial prophylaxis when member is new to Alhemo therapy
    ReferenceSee Appendix D for full definition and examples
    Serious bleeding episodes — sites and examples defining serious bleeds
    Examples of serious bleeding episodesIntracranial; neck/throat; gastrointestinal; joints (hemarthrosis); muscles (deep compartments such as iliopsoas, calf, forearm); mucous membranes of mouth, nose, and genitourinary tract.
    ContextOne serious spontaneous bleed meets eligibility for new-to-therapy prophylaxis when not previously using factor prophylaxis

    Billing and Code Summary

    Billing Rule

    Operational billing note: use J7173

    Operational reminder: use HCPCS code J7173 (Injection, concizumab-mtci, 0.5 mg) when billing concizumab-mtci (Alhemo) per the policy coding section.

    • Use J7173 for concizumab-mtci (0.5 mg) claims.
    • Ensure PA and claims align with policy coding guidance.

    Background Information

    Concizumab‑mtci (Alhemo) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients aged ≥ 12 years with hemophilia A or B, with or without inhibitors. The usual regimen includes a one‑time loading dose of 1 mg/kg subcutaneously followed by daily maintenance dosing (typical maintenance start 4 weeks after initiation); maintenance dosing may be individualized using plasma concentration guidance. The policy notes product availability as single‑patient‑use prefilled pens in multiple strengths and specifies billing using HCPCS code J7173 for concizumab‑mtci (0.5 mg) claims.

    Policy Summary
    PayerHealth Net
    PolicyConcizumab-mtci (Alhemo) prophylaxis for hemophilia A and B
    Policy CodePolicy CP.PHAR.625
    Change TypeMaterial coverage and operational updates (codes, indications, approval durations, exclusions)
    Effective DateDec 20, 2024
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation demonstrating diagnosis, prescriber specialty, weight, prior therapy failures or contraindications, dosing, and relevant plasma concentration data.
    SourceLink
    On This Page
    Coverage Criteria for Concizumab-mtci (Alhemo)Coding and Laboratory ThresholdsProvider Requirements, Prior Authorization, and BillingInitial Therapy Criteria and DosingCriteria for Continued TherapyStep Therapy Requirements and ExceptionsProduct Strengths and Quantity InformationSite of Care and AdministrationDefinitions and Clinical TermsBilling and Code SummaryBackground Information
    Alhemo is not prescribed concurrently with another hemophilia prophylaxis agent (e.g., bypassing agents, prophylactic FVIII/FIX products, Qfitlia, Hympavzi, Hemlibra). On-demand usage of FVIII, FIX, or bypassing agents may continue.
    Weight: Documentation of current body weight (kg).
    Dosing limits: Dose does not exceed both of the following: one loading dose of 1 mg/kg and maintenance dose of 0.25 mg/kg per day.
    Plasma concentration: Member has not had 2 consecutive Alhemo plasma concentrations < 200 ng/mL.

    If plasma concentration is < 200 ng/mL at two consecutive measurements, benefits should be reevaluated (see Appendix D).

    Dose adjustment by concentration: New maintenance dose must not exceed the following per Alhemo plasma concentration: (a) < 200 ng/mL: 0.25 mg/kg/day; (b) 200 to 4,000 ng/mL: 0.2 mg/kg/day; (c) > 4,000 ng/mL: 0.15 mg/kg/day.

    Dose individualization per Concizumab ELISA (Appendix D).

    See Appendix D for definitions
    FIX level for moderately severe to severe hemophilia B
    FIX threshold (moderately severe to severe hemophilia B)≤ 2%
    ContextUsed to define moderately severe to severe hemophilia B for eligibility when new to prophylaxis
    Source appendix referenceSee Appendix D for definitions
    Alhemo plasma concentration thresholds for dosing optimization
    Plasma concentration ≤ 200 ng/mLIncrease maintenance dose to 0.25 mg/kg SC once daily
    Plasma concentration 200–4,000 ng/mLMaintain maintenance dose at 0.2 mg/kg SC once daily
    Plasma concentration > 4,000 ng/mLReduce maintenance dose to 0.15 mg/kg SC once daily

    Submit claims using HCPCS code J7173 (Injection, concizumab-mtci, 0.5 mg) and ensure the prior authorization follows the clinical coverage criteria in this policy.

    • Code to use: J7173 = Injection, concizumab-mtci, 0.5 mg.
    • Follow the policy coverage criteria when submitting PA and claims.
    Step Therapy

    Step therapy / prior treatment requirements

    Step therapy requires prescriber-documented failure of specified prior therapies unless contraindicated: for hemophilia A without inhibitors, documented failure of an FVIII product used for routine prophylaxis and failure of Hemlibra; for hemophilia B without inhibitors, documented failure of a FIX product.

    • Document clinical failure or contraindication to FVIII (and Hemlibra for hemophilia A) or FIX (for hemophilia B).
    • Prior authorization may be required for comparator products.
    Step Therapy

    Step therapy bypass for Illinois HIM

    Illinois HIM requests are exempt from the step therapy requirement effective 1/1/2026 per IL HB 5395; include state-specific exception when processing IL HIM prior authorizations.

    • Step therapy requirements do not apply for Illinois HIM requests as of 1/1/2026 per IL HB 5395.
    • Apply the IL HIM bypass when applicable to the member's line of business.
    Documentation Required

    Required documentation for prior authorization

    Provide supporting documentation with the prior authorization request, including office chart notes and laboratory results, evidence of hematologist involvement or consultation, current body weight in kg, and documentation of prior therapy failures or contraindications.

    • Office chart notes and lab results supporting the diagnosis and clinical course.
    • Evidence of hematologist involvement or that treatment was prescribed in consultation with a hematologist.
    • Prior therapy details: failures, adverse effects, or contraindications, and current body weight (kg).
    Billing Rule

    Billing code for concizumab-mtci

    Bill concizumab-mtci using HCPCS code J7173 (Injection, concizumab-mtci, 0.5 mg) as specified in the coding section of the policy.

    • HCPCS J7173 = Injection, concizumab-mtci, 0.5 mg.
    • Reference the most up-to-date coding guidance prior to claim submission.
    Denial Risk

    Failure to submit required documentation may result in denial

    Failure to submit required documentation (office notes, labs, or other clinical information) demonstrating the member meets all approval criteria may result in denial of the prior authorization request.

    Denial Risk

    Concurrent prophylactic therapy excluded

    Concurrent prophylactic use of Hemlibra, bypassing agents, prophylactic FVIII, or prophylactic FIX products while on Alhemo is an exclusion and may trigger denial if not discontinued; on‑demand use of FVIII, FIX, or bypassing agents is allowable.

    • Concurrent prophylactic Hemlibra, bypassing agents, FVIII, or FIX is excluded and will preclude coverage.
    • On‑demand use of FVIII, FIX, or bypassing agents may continue as described in the policy.
    Dosing limits: One loading dose of 1 mg/kg; maintenance dose ≤ 0.25 mg/kg/day.

    Initial therapy

    Initial dosing and billing

    Initial dosing: Loading dose of 1 mg/kg SC one time, followed by maintenance dosing of 0.2 mg/kg SC once daily starting 4 weeks after initiation; adjust maintenance to 0.25 mg/kg if plasma concentration ≤ 200 ng/mL per Appendix D.

    Appendix D provides plasma concentration-based adjustments; historical ELISA monitoring noted but documentation requirements removed later.

    Billing for initial therapy: Bill concizumab-mtci using HCPCS code J7173 (Injection, concizumab-mtci, 0.5 mg) as specified in coding section.

    Providers should reference most up-to-date coding guidance prior to claim submission.

    Approval duration by line of business: For Medicaid/HIM/ICHRA: continued approval duration set to 12 months. For Commercial: continued approval 6 months or to the member's renewal date, whichever is longer.

    Initial approval durations were also modified; see policy revision history.

    Monitoring: Requirements for documentation and provider attestations of Concizumab ELISA were removed in 2Q2026; routine clinical monitoring is referenced historically but ELISA attestations no longer required.

    Policy previously required ELISA at 4-8 weeks and routine monitoring thereafter; these specific documentation requirements have been removed.

    SourceAppendix D: General Information
    Alhemo dosing — loading dose and maintenance dosing definitions
    Loading dose1 mg/kg SC one time (single loading dose)
    Standard maintenance dose0.2 mg/kg SC once daily starting 4 weeks after initiation
    Maximum individualized maintenanceUp to 0.25 mg/kg SC once daily if Alhemo plasma concentration ≤ 200 ng/mL